COPENHAGEN, Denmark, Jan. 23, 2024 /PRNewswire/ -- Vesper Bio ApS ('Vesper' or 'the Company'), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the Company has been awarded a grant (MJFF-024128) worth c.US$873,000 by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to assess sortilin inhibition in Parkinson's disease.

丹麦哥本哈根，2024年1月23日/PRNewswire/-Vesper Bio-ApS（“Vesper”或“该公司”），临床阶段生物技术和分拣蛋白受体生物学的世界领导者，今天宣布该公司已获得迈克尔·J·福克斯帕金森病研究基金会（MJFF）授予的价值约873000美元的赠款（MJFF-024128），用于评估分拣蛋白对帕金森病的抑制作用。

The project will commence in January 2024 and is led by principal investigators Louise Klem (Senior Research Scientist) and Anders Nykjær (CSO and Founder)..

该项目将于2024年1月开始，由首席研究员路易斯·克莱姆（高级研究科学家）和安德斯·尼基尔（CSO和创始人）领导。。

The grant was awarded under the MJFF's Parkinson's Disease Therapeutics Pipeline Program (Pre-Clinical). The program seeks to advance preclinical testing of promising therapeutic developments that address unmet medical needs in people with Parkinson's disease. The program is set up to fund therapeutic development with a clear focus to prevent, stop, or delay disease progression or to reduce the challenges of daily symptoms..

该赠款是根据MJFF的帕金森病治疗管道计划（临床前）授予的。该项目旨在推进有希望的治疗发展的临床前测试，以解决帕金森病患者未满足的医疗需求。该计划旨在资助治疗开发，明确重点是预防，阻止或延缓疾病进展或减少日常症状的挑战。。

Vesper is currently expediting the development of VES001 for FTD(GRN) through ongoing Phase I studies that will include a Phase Ib Proof-of Concept in GRN mutation carriers in advance of potentially registrational Phase II/III trials, and for Phase I readiness of VES002, a treatment focused on a second central nervous system indication..

Vesper目前正在通过正在进行的I期研究加速FTD（GRN）VES001的开发，该研究将包括在潜在的注册II/III期试验之前在GRN突变携带者中进行Ib期概念验证，以及VES002的I期准备就绪，该治疗侧重于第二个中枢神经系统适应症。。

Anders Nykjaer, MD, PhD Chief Scientific Officer of Vesper Bio, commented, 'Vesper has developed orally administered, small molecule, sortilin inhibitors that elevate central progranulin levels and these hold promise for treating certain CNS diseases, including Parkinson's disease. This grant by The Michael J.

Vesper Bio首席科学官、医学博士Anders Nykjaer评论道：“Vesper开发了口服小分子分拣蛋白抑制剂，可提高中枢颗粒蛋白前体水平，有望治疗某些中枢神经系统疾病，包括帕金森病。这项由迈克尔·J。

Fox Foundation's Parkinson's Disease Therapeutics Pipeline Program will support our research as we look to further demonstrate the efficacy of this novel therapy against this terrible disease.'.

福克斯基金会的帕金森病治疗管道计划将支持我们的研究，因为我们希望进一步证明这种新疗法对这种可怕疾病的疗效。”。

Jessica Tome Garcia, PhD, Associate Director, Translational Research at MJFF, said, 'MJFF greatly values research into the biological underpinnings of Parkinson's disease and leveraging that insight for new treatment ideas. We are proud to fund the work of researchers at Vesper Bio as they investigate new ways to fulfil the unmet needs of people with Parkinson's.'.

MJFF转化研究副主任杰西卡·托姆·加西亚（JessicaTomeGarcia）博士说，“MJFF非常重视对帕金森病生物学基础的研究，并利用这一见识提出新的治疗思路。我们很自豪能资助Vesper Bio研究人员的工作，因为他们正在研究满足帕金森氏症患者未满足需求的新方法。

About Vesper Bio

关于Vesper Bio

Vesper is a clinical stage biotech and world leader in sortilin receptor biology. Its lead program uses a sortilin inhibitor to rebalance levels of progranulin in patients where the sortilin receptor would otherwise reduce circulating and extracellular progranulin, contributing to disease. Progranulin is a protein that the body uses to regulate cell growth, survival, repair and avoid inflammation.

Vesper是临床阶段生物技术公司，也是分拣蛋白受体生物学领域的世界领先者。它的领导项目使用分拣蛋白抑制剂来重新平衡患者的颗粒蛋白前体水平，否则分拣蛋白受体会减少循环和细胞外颗粒蛋白前体，从而导致疾病。颗粒体蛋白前体是一种蛋白质，人体用于调节细胞生长，存活，修复和避免炎症。

Low progranulin levels are believed to be a factor in cell dysfunction and damage in a range of indications across neurology. By normalizing progranulin levels, Vesper believes its compounds will have a disease modifying effect, protecting and preserving the remaining cells..

在整个神经病学的一系列适应症中，低颗粒蛋白原水平被认为是细胞功能障碍和损伤的一个因素。Vesper认为，通过使颗粒蛋白原水平正常化，其化合物将具有改善疾病的作用，保护和保存剩余的细胞。。

Its lead compound, VES001, is a patient friendly, first-in-class, brain penetrant, oral treatment which targets progranulin deficiency, a major underlying cause of Frontotemporal Dementia (FTD). As an orally delivered small molecule, VES001 is able to cross the blood brain barrier and is an ideal dosing method among these patients due to their rapidly declining mental state..

它的先导化合物VES001是一种对患者友好的，一流的脑渗透剂，口服治疗，针对颗粒蛋白前体缺乏症，这是额颞叶痴呆（FTD）的主要根本原因。作为一种口服小分子，VES001能够穿过血脑屏障，由于其精神状态迅速下降，因此是这些患者的理想给药方法。。

For further information please visit, https://www.vesperbio.com/.

For further information please visit,https://www.vesperbio.com/.

SOURCE Vesper Bio

来源Vesper Bio